Pilot study of combination chemotherapy using irinotecan plus S-1 for metastatic pancreatic cancer

Oncology

Volumn 75, Issue 1-2, 2008, Pages 67-70

  Shitara, Kohei ^a,d   Komatsu, Yoshito ^b,c   Yuki, Satoshi ^b,c   Munakata, Masaki ^a   Muto, Osamu ^a   Shimaya, Sen ^a   Sakata, Yuh ^a  

^a Misawa City Hospital   (Japan)

^b HOKKAIDO UNIVERSITY   (Japan)

^c Hokkaido Gastrointestinal Cancer Study Group   (Japan)

^d Misawa City Hospital   (Japan)

Author keywords

Chemotherapy; Irinotecan; Pancreatic cancer; S 1

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; ANTIBIOTIC AGENT; CISPLATIN; DOCETAXEL; FLUOROURACIL; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IRINOTECAN; PACLITAXEL;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PANCREAS ADENOCARCINOMA; PILOT STUDY; PRIORITY JOURNAL; RASH; SALVAGE THERAPY; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; DRUG COMBINATIONS; FEASIBILITY STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; OXONIC ACID; PANCREATIC NEOPLASMS; PILOT PROJECTS; PROSPECTIVE STUDIES; TEGAFUR; TREATMENT OUTCOME;

EID: 50049128450     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000151742     Document Type: Article

References (8)

1. Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15:2403-2413.
2. Cunningham D, Chau I, Stocken C, Davies C, Dunn J, Valle J: Phase III randomised comparison of gemcitabine (GEM) versus gemcitabine plus capecitabine (GEM-CAP) in patients with advanced pancreatic cancer. European Cancer Conference (ECCO 13) (abstract PS11). Eur J Cancer Suppl 2005;3:4.
3. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, Campos D, Lim R, Ding K, Clark G, Voskoglou-Nomikos T, Ptasynski M, Parulekar W; National Cancer Institute of Canada Clinical Trials Group: Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007;25:1960-1966.
4. Ueno H, Okusaka T, Ikeda M, Takezako Y, Morizane C: An early phase II study of S-1 in patients with metastatic pancreatic cancer. Oncology 2005;68:171-178.
5. Okusaka T, Funakoshi A, Furuse J, Boku N, Yamao K, Ohkawa S, Saito H: Phase II study of S-1 for metastatic pancreatic cancer. Cancer Chemother Pharmacol 2008;61:615-621.
6. Sakata Y, Shimada Y, Yoshino M, Kambe M, Futatsuki K, Nakao I, Ogawa N, Wakui A, Taguchi T: A late phase II study of CPT-11, irinotecan hydrochloride, in patients with advanced pancreatic cancer: CPT-11 Study Group on Gastrointestinal Cancer. Gan To Kagaku Ryoho 1994;21:1039-1046.
7. Ueno H, Okusaka T, Funakoshi A, Ishii H, Yamao K, Ishikawa O, Ohkawa S, Saitoh S: A phase II study of weekly irinotecan as firstline therapy for patients with metastatic pancreatic cancer. Cancer Chemother Pharmacol 2007;59:447-454.
8. Komatsu Y, Yuuki S, Fuse N, Takei M, Miyagishima T, Kudo M, Hashino S, Asaka M, Sakata Y: Phase I/II clinical study of irinotecan plus S-1 in patients with advanced gastric cancer (abstract 4191). J Clin Oncol 2004;22:14S.